Hollis-Eden Pharmaceuticals Inc. Presents Positive Preclinical Data On Compounds Targeting Hormone Refractory Prostate Cancer

SAN DIEGO--(BUSINESS WIRE)--Sept. 13, 2006--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) announced today that its scientists presented data detailing the activity of its steroid compounds in preclinical models of hormone refractory prostate cancer (HRPC). The results presented at the 12th International Congress on Hormonal Steroids, Hormones & Cancer being held September 13-16, 2006, in Athens, Greece, show that these compounds can inhibit adrenal steroid-induced generation and proliferation of prostate cancer tumors common in late-stage disease.